Related Experiment Video

Updated: Jun 17, 2026

Minimally Invasive Transverse Aortic Constriction in Mice
07:40

Minimally Invasive Transverse Aortic Constriction in Mice

Published on: March 14, 2017

21.9K

Mavacamten as an Effective Treatment for HCM With Latent Exercise-Induced Obstruction: A Case Report

Nikitha Murthy1, Brian Diep1, Jonathan Evans1

  • 1Division of Cardiology, Loma Linda University Health, Loma Linda, California, USA, lluh.org.

Case Reports in Cardiology
|April 20, 2026
PubMed

Insights

Mavacamten effectively treats symptomatic hypertrophic cardiomyopathy (HCM) with exercise-induced obstruction. This myosin inhibitor improved patient symptoms, even without resting obstruction, highlighting its potential in a broader HCM population.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Hypertrophic cardiomyopathy (HCM) is a myocardial disorder causing left ventricular hypertrophy and symptoms, especially during exercise.
  • Obstructive HCM can be treated with mavacamten, a myosin inhibitor that reduces obstruction and symptoms.

Purpose of the Study:

  • To evaluate the efficacy of mavacamten in a patient with symptomatic HCM and exercise-induced left ventricular outflow tract obstruction (LVOTO).

Main Methods:

  • Case presentation of a symptomatic HCM patient.
  • Treadmill stress echocardiography to assess for exercise-induced LVOTO.
  • Treatment with mavacamten.

Main Results:

  • The patient had no resting LVOTO but demonstrated obstruction during exercise.
  • Symptomatic improvement was observed after mavacamten treatment.

Conclusions:

  • Symptomatic HCM patients without resting gradients may benefit from exercise stress testing to identify obstructive HCM.
  • Mavacamten may be a safe and effective treatment for patients with exercise-induced LVOTO.
Abstract

Keywords:
Valsalvahypertrophic cardiomyopathymavacamtentreadmill stress echocardiography

More Related Videos

Operating Transverse Aortic Constriction with Absorbable Suture to Obtain Transient Myocardial Hypertrophy07:02

Operating Transverse Aortic Constriction with Absorbable Suture to Obtain Transient Myocardial Hypertrophy

Published on: September 9, 2020

7.2K
Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension07:38

Comprehensive Echocardiographic Assessment of Right Ventricle Function in a Rat Model of Pulmonary Arterial Hypertension

Published on: January 20, 2023

5.1K

Related Concept Videos

Mitral Valve Prolapse II: Assessment and Management01:22

Mitral Valve Prolapse II: Assessment and Management

IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular tachycardia.
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...